Business Context and Reporting Period
This Form 8-K Current Report, dated February 18, 2022, details material definitive agreements entered into by Akebia Therapeutics, Inc. ("Akebia") with Vifor Pharma (International) Ltd. ("Vifor Pharma") and amendments to existing loan agreements. The filing focuses on the commercialization strategy for vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease (CKD).
Key Financial Metrics and Agreements
- Upfront Payment: Vifor Pharma agreed to pay Akebia $25 million upfront, replacing a previously disclosed milestone payment contingent on FDA approval.
- Equity Investment: Vifor Pharma agreed to purchase 4,000,000 shares of Akebia common stock for a total of $20 million.
- Working Capital Facility: Vifor Pharma will contribute $40 million to a Working Capital Fund to partially fund Akebia's costs for purchasing vadadustat from contract manufacturers. Akebia will repay this amount over time.
- Profit Share Structure: The agreement maintains a profit share arrangement where Akebia receives approximately 66% of the profit, net of certain pre-specified costs.
- Debt Covenant Waiver: Akebia secured a waiver regarding a financial statement covenant in its existing Loan Agreement with BioPharma Credit PLC and added the Working Capital Fund to the definition of Permitted Indebtedness.
Material Changes Versus Prior Period
The primary material change is the restructuring of the commercial relationship with Vifor Pharma. The Second Amended and Restated License Agreement converts a future milestone payment of $25 million into an immediate upfront payment. Additionally, the agreement introduces a new $40 million working capital facility and a concurrent $20 million equity investment, which were not present in the prior agreement dated April 8, 2019. The filing also notes an amendment to the Loan Agreement to accommodate the new working capital facility.
Guidance, Outlook, and Risks
Commercial Rights: Akebia retains rights to commercialize vadadustat for the non-dialysis dependent CKD market and to sell to dialysis organizations outside the defined "Supply Group." Vifor Pharma is granted an exclusive license to sell to the Supply Group in the United States.
Termination Provisions: Vifor Pharma may terminate the agreement with 30 months' notice after the first anniversary of FDA approval. Akebia may terminate for convenience subject to specific timing and regulatory events, potentially incurring a termination fee.
Risks and Contingencies: The filing highlights significant risks including FDA approval outcomes, the ability of both parties to satisfy obligations, manufacturing and supply risks, and the impact of the COVID-19 pandemic. Forward-looking statements regarding profit sharing and commercialization are subject to these uncertainties.
Key Facts for Investor Verification
- Confirmation of the $25 million upfront payment receipt and the $20 million equity issuance closing date (expected on or about February 23, 2022).
- Details of the repayment schedule and terms for the $40 million Working Capital Fund.
- Specific definitions of the "Supply Group" and the scope of territories where Akebia retains commercialization rights.
- Impact of the Loan Agreement amendment on Akebia's existing debt covenants and acceleration rights.
- Current status of the New Drug Application (NDA) for vadadustat with the FDA.